Go Pro
NASDAQ:XAIR

Beyond Air Q1 2027 Earnings Report

Beyond Air logo
$7.49 -0.85 (-10.19%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$7.39 -0.10 (-1.34%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Beyond Air EPS Results

Actual EPS
N/A
Consensus EPS
-$0.51
Beat/Miss
N/A
One Year Ago EPS
N/A

Beyond Air Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.86 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Beyond Air Announcement Details

Quarter
Q1 2027
Time
Before Market Opens
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Beyond Air Earnings Headlines

Beyond Air (XAIR) Q4 2026 Earnings Call Transcript
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
See More Beyond Air Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beyond Air? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beyond Air and other key companies, straight to your email.

About Beyond Air

Beyond Air (NASDAQ:XAIR) is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity. Beyond Air is also evaluating LungFit® PT for pulmonary tuberculosis and LungFit® C for viral and bacterial lung infections, including potential applications in acute respiratory distress syndrome. These programs position the LungFit platform as a versatile therapy that may complement or improve upon existing treatment options.

Beyond Air operates primarily in the United States and collaborates with academic and clinical research centers to advance its clinical trials. The company engages with regulatory authorities, including the U.S. Food and Drug Administration, to pursue marketing approvals and expanded indications for its nitric oxide therapies. By building strategic partnerships, Beyond Air aims to broaden access to its platform technology across diverse healthcare markets.

Founded in 2013 and headquartered in East Setauket, New York, Beyond Air is led by President and Chief Executive Officer Nicholas E. Caputo, a life sciences executive with extensive experience in medical device development and regulatory strategy. Under his leadership, the company has advanced multiple product candidates through early-stage clinical evaluation and continues to build a pipeline of inhaled gas therapies designed to improve outcomes for patients with challenging respiratory conditions.

View Beyond Air Profile